| |
Total cohort
|
Control
|
MCI
|
AD
|
|---|
|
Urine
| | | | |
|
Participants
|
556
|
171
|
209
|
176
|
|
Male/female
|
269/287
|
83/88
|
95/114
|
91/85
|
|
Mean age (SD)
|
76.24 (5.76)
|
75.85 (5.17)
|
76.33 (6.03)
|
76.53 (5.99)
|
|
MMSE score
|
25.67 (4.59)
|
28.73 (1.92)
|
26.86 (2.75)
|
21.17 (4.87)
|
|
CDR
|
0.56 (0.51)
|
0.07 (0.18)
|
0.49 (0.08)
|
1.10 (0.54)
|
|
Reported SSRI medication
|
43
|
4
|
16
|
23
|
|
Serum
| | | | |
|
Participants
|
354
|
86
|
165
|
103
|
|
Male/female
|
165/189
|
44/42
|
71/94
|
50/53
|
|
Mean age
|
76.95 (6.13)
|
75.97 (5.67)
|
77.50 (6.49)
|
76.91 (5.84)
|
|
MMSE score
|
25.57 (4.37)
|
28.80 (1.99)
|
26.73 (2.24)
|
21.06 (4.79)
|
|
CDR
|
0.59 (0.54)
|
0.04 (0.16)
|
0.49 (0.11)
|
1.16 (0.55)
|
|
Reported SSRI medication
|
30
|
1
|
11
|
18
|
- Overview of the sample cohort used in the study. SSRI selective serotonin reuptake inhibitor, MCI mild cognitive impairment, AD Alzheimer’s disease, MMSE Mini-Mental State Examination score, CDR Clinical Dementia Rating
